Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc. discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Acumen Pharma reports strong Q1 earnings, anticipates Alzheimer's trial results

Acumen Pharma's Q1 2023 earnings call highlighted strong financials, progress in the INTERCEPT-AD trial, and upcoming data disclosures. The company faces challenges in trial design and financial management but has opportunities to demonstrate efficacy and attract partnerships.

Acumen Pharmaceuticals Reports Positive Phase I Results and Strong Financial Position

Acumen Pharmaceuticals showcased positive Phase I results for ACU193, reflecting progress in Alzheimer's disease treatment. The company's financial update revealed a strong cash position and a promising cash runway. While challenges exist in integrating Phase I data and exploring new dosing methods, opportunities arise for advancing the program and forming strategic partnerships.

Acumen Pharma Advances ACU193 for Alzheimer's Treatment, Secures Funding

Acumen Pharma's Q3 2023 earnings call showcased significant advancements in ACU193 development, strong financial positioning, and promising partnerships. However, addressing concerns related to biomarker data, dose selection, and baseline characteristics will be critical for future success. The company's progress in FDA interaction and the development of a subcutaneous form of ACU193 present promising opportunities for growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.

CHARLOTTESVILLE, Va., April 16, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present the comprehensive clinical and biomarker results from its positive Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) in early AD during an Emerging Science Session at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver on April 16, 2024. The results build upon Acumen's prior presentations at the AD/PD™ 2024 Annual Meeting and positive topline data first announced in July 2023 and will be presented together for the first time with expanded analysis.

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

CHARLOTTESVILLE, Va. and BASEL, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), has signed a collaboration agreement with Lonza, a global partner to the pharmaceutical, biotech and nutraceutical markets. The agreement covers the manufacture of sabirnetug (ACU193), an antibody targeting toxic soluble AβOs for the treatment of AD, for clinical development and commercialization, if approved.

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease

Acumen Pharmaceuticals (ABOS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Acumen Pharmaceuticals (ABOS) Stock Might be a Great Pick

Acumen Pharmaceuticals (ABOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Call Transcript

CHARLOTTESVILLE, Va., March 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the full year ended December 31, 2023 and provided a business update.

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Ayr Wellness Inc. (AYRWF) have performed compared to their sector so far this year.

Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year?

CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2023 financial results on Tuesday, March 26, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

CHARLOTTESVILLE, Va., March 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat as part of the Stifel 2024 CNS Days on Tuesday, March 19, 2024, at 12:00 p.m. ET.

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

- Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug's downstream pharmacological effects in the brain in early AD

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.

Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year?

-   Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today the appointment of James Doherty, Ph.D., as President and Chief Development Officer, effective February 1, 2024, reporting to Daniel O'Connell, Chief Executive Officer. Dr. Doherty's responsibilities will include oversight of clinical and non-clinical development, chemistry, manufacturing & controls and regulatory functions.

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

Johnson & Johnson

UnitedHealth Group

As investors, we are often looking to diversify our portfolios. Especially with the wild AI craze in the past year, many investors already hold positions in AI or other technology companies.

Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot

CareTrust REIT

Medtronic

Aging stocks (or longevity stocks) are drawing attention from investors for obvious reasons. The Baby Boomer generation is now almost fully retired, and Gen X is right on its heels.

3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom

CHARLOTTESVILLE, Va., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will present at the 42nd Annual J.P.

Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q3 2023 Earnings Conference Call November 13, 2023 08:00 AM ET Company Participants Alex Braun - Head-IR Daniel O'Connell - CEO Eric Siemers - Chief Medical Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participants Thomas Shrader - BTIG Pete Stavropoulos - Cantor Fitzgerald Colin Bristow - UBS Presentation Operator Good day, ladies and gentlemen. Thank you for standing by.

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2023 Earnings Call Transcript

CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the third quarter of 2023 and provided a business update.

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (“AβOs”) for the treatment of Alzheimer's disease (“AD”), today announced that it has entered into a senior secured loan and security agreement (the “Loan Agreement”) with K2 HealthVentures, a healthcare-focused specialty finance company.

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, Nov. 14, 2023 at 2:25 p.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report third quarter financial results on Monday, Nov. 13, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023

Expect to initiate Phase 1 development in mid-2024 to compare pharmacokinetics of subcutaneous form to intravenous form of ACU193 Expect to initiate Phase 1 development in mid-2024 to compare pharmacokinetics of subcutaneous form to intravenous form of ACU193

Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

CHARLOTTESVILLE, Va., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the UBS Biopharma Conference on Thursday, Nov. 9, 2023 at 10:00 a.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference

CHARLOTTESVILLE, Va. and INDIANAPOLIS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that it will present deeper insights and new exploratory findings from its Phase 1 INTERCEPT-AD trial evaluating ACU193, the first clinical-stage AβO-directed antibody therapy for early AD, at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference taking place in Boston and online from October 24-27, 2023. INTERCEPT-AD was selected to be featured in a symposium on Friday, October 27, and data from exploratory analyses of the Phase 1 trial will also be shared in two in-person and two virtual poster presentations.

Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's During Symposium at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD)

Acumen Pharmaceuticals' ACU193 shows promise as a potential treatment for early-stage Alzheimer's Disease, targeting amyloid beta oligomers with a more favorable safety profile. Q2 earnings show increased operating expenses and a net loss expansion, but a recent capital injection extends the cash runway and lowers the threat of near-term dilution. Market sentiment is cautious, but the Phase 1 results and financial stability suggest a potential buying opportunity for risk-tolerant investors.

News for Acumen Pharmaceuticals Stock (ABOS)